Background {#section5-1753466619879832}
==========

Bronchopneumonia, also known as lobular pneumonia, is the most common cause of hospitalizations in childhood. For children aged under 5 years in China, the incidence of bronchopneumonia ranged from 0.06 to 0.27 episodes per person-year, and the mortality rate was about 184--1223/100,000.^[@bibr1-1753466619879832]^ Repeated hospitalizations with infectious disease increase the risk of hospital-acquired infection and increase the socioeconomic burden.^[@bibr2-1753466619879832],[@bibr3-1753466619879832]^ Immunoglobulin E (IgE) is produced by plasma cells in the *lamina propria* of the nasopharynx, tonsils, bronchus, and gastrointestinal mucosa and mediates type I allergy,^[@bibr4-1753466619879832]^ such as bronchial asthma^[@bibr4-1753466619879832],[@bibr5-1753466619879832]^ and rhinitis,^[@bibr6-1753466619879832],[@bibr7-1753466619879832]^ and is associated with the prevalence of lower airway infections.^[@bibr8-1753466619879832]^ Children with asthma and chronic sinusitis have a significantly increased risk of bronchopneumonia and pneumonia,^[@bibr9-1753466619879832],[@bibr10-1753466619879832]^ suggesting that IgE levels may be associated with the occurrence of bronchopneumonia.

There were several case reports showing that children with recurrent bronchopneumonia had high IgE levels,^[@bibr11-1753466619879832],[@bibr12-1753466619879832]^ and that changes in IgE levels may correlate with the severity of bronchopneumonia in children.^[@bibr13-1753466619879832]^ Meanwhile, children with bronchopneumonia, especially those with severe pneumonia, were often accompanied by immune dysfunction.^[@bibr14-1753466619879832],[@bibr15-1753466619879832]^ The occurrence and development of lower respiratory tract diseases can be affected by dysfunction of immune system,^[@bibr16-1753466619879832]^ which may lead to the recurrence of bronchopneumonia in children.

We speculated that the levels of IgE might be associated with repeated hospitalizations of bronchopneumonia in children. In the current study, the readmission rate of children with bronchopneumonia in 12 months following the index hospitalization was calculated; we further measured the plasma levels of IgE in children with bronchopneumonia and investigated the relationship between IgE levels and rehospitalization in children with bronchopneumonia.

Methods {#section6-1753466619879832}
=======

Study populations {#section7-1753466619879832}
-----------------

This study enrolled pediatric bronchopneumonia patients who were hospitalized between 1 January 2015 and 31 December 2016 at Minhang Branch, Zhongshan Hospital, Fudan University, Shanghai, China. The diagnosis of bronchopneumonia was usually based on the clinical features and supported by the chest radiography:^[@bibr17-1753466619879832]^ (a) if cough persists for more than 1 week, tends to recur, or is accompanied by fever, or listening to the chest reveals abnormal breath sounds, such as crackles that suggest fluid in the lungs; (b) infection of the lower respiratory tract typically presents radiologically as multifocal bronchopneumonia or lobular pneumonia. Asthma was diagnosed according to the 2016 guideline for the diagnosis and optimal management of asthma in children.^[@bibr17-1753466619879832]^ Inclusion criteria were: (a) the patients were between the ages of 1 and 12; (b) the first discharge diagnoses was registered as 'bronchopneumonia' or 'lobular pneumonia' in the hospital's electronic medical records; (c) children who survived the index hospitalization. Exclusion criteria were: (a) children whose parents or guardians refused regular treatment for the children or had the children discharged from the hospital in advance; (b) children with incomplete medical records. The study flowchart is shown in [Figure 1](#fig1-1753466619879832){ref-type="fig"}.

![Study flowchart.\
IgE, immunoglobulin E.](10.1177_1753466619879832-fig1){#fig1-1753466619879832}

The study was approved by the Ethics Committee of Minhang Branch, Zhongshan Hospital, Fudan University, Shanghai, and waived the need for formal patient consent because the retrospective study only used encrypted clinical data and presented no risk to participants.

Data collection {#section8-1753466619879832}
---------------

We initially collected demographic data; the number of hospitalizations within the first 12 months of the index hospitalization; dates and results of inpatient laboratory blood tests from the hospital's electronic records. Readmission for bronchopneumonia within the first 12 months of the index hospitalization was identified in the hospital database or telephone follow up. Additional data were manually extracted including family history of allergy, comorbidities, and time from discharge to readmission. Comorbidities, including bronchial asthma, agranulocytosis, anemia, and acute otitis media (AOM), were diagnosed during the index hospitalization or previously.

The primary outcome of the study was bronchopneumonia-related readmission within 12 months. The rate of rehospitalization = (number of readmission patients within 12 months/number of discharged patients in the year) × 100%.

Laboratory studies {#section9-1753466619879832}
------------------

The blood biochemical test and infection marking in peripheral venous blood were detected within 24 h of admission using the Sysmex xs-800i automatic hematology analyzer (SYSMEX Corp., Kobe, Japan) and total bilirubin and alanine aminotransferase (ALT) were examined using a Vitros350 automatic biochemical analyzer (Johnson & Johnson, New Jersey, USA). High-sensitivity C-reactive protein (hs-CRP) was determined using avidin--biotin--horseradish peroxidase complex enzyme-linked immunosorbent assay (ABC-ELISA). IgE levels were measured using an IMMAGE800 specific protein analyzer (Beckman Coulter, Inc., California, USA). The normal range of IgE in our hospital was set up at ⩽165 IU/ml.

Statistical analyses {#section10-1753466619879832}
--------------------

Data were analyzed using SPSS 19.0 (IBM, Chicago, IL, USA). Normally distributed data were expressed in mean ± standard deviation and we used the Student's *t* test to compare the continuous data between two groups, include white blood cell count, hemoglobin, platelets, and length of stay. Non-normally distributed data were expressed in median (interquartile range, IQR) and compared using the nonparametric Mann--Whitney test, including hs-CRP, total bilirubin, ALT and IgE. Differences in trend of change were examined using the Jonckheere--Terpstra test.

For binary outcomes, associations between first inpatient available IgE during the index hospitalization and outcomes were estimated using univariate analysis. Age and sex, and all other variables with *p* \< 0.15 in univariate analysis were entered into multivariate regression analysis. The association with IgE was estimated using multivariate logistic regression models and Kaplan--Meier survival curves. Sensitivity analyses were performed to estimate the associations between the IgE levels and the comorbidities, laboratory findings and hospitalization time, adjusting for sex and age, with a higher IgE level cut-off (\>165 IU/ml, the upper limit of normal range). IgE levels were distributed according to quartile. The first quartile, the median and the third quartile were \<32.3 IU/ml, 32.3--95 IU/ml, 95--251 IU/ml and ⩾251 IU/ml respectively; IgE levels were distributed into four categories with thresholds corresponding to equal or below the upper normal limit (UNL ⩽ 165 IU/ml), equal or below two times the UNL (165--330 IU/ml), equal or below three times the UNL (330--495 IU/ml) and higher than three times the UNL (\>495 IU/ml), or by combining IgE and bronchial asthma: IgE ⩽ 165 IU/ml and without bronchial asthma, IgE ⩽ 165 IU/ml and with bronchial asthma, IgE \> 165 IU/ml and without bronchial asthma and IgE \> 165 IU/ml and with bronchial asthma. *p* \< 0.05 was considered statistically significant.

Results {#section11-1753466619879832}
=======

Patient demographic and baseline characteristics {#section12-1753466619879832}
------------------------------------------------

In total, 1561 children with bronchopneumonia were hospitalized between 1 January 2015 and 31 December 2016. A total of 233 children, aged under 1 year or over 12 years were excluded. And 229 children were also excluded due to other causes, as detailed in the study flowchart ([Figure 1](#fig1-1753466619879832){ref-type="fig"}). Finally, 1099 children were included in the analysis. In total, 125 (11.4%) children were readmitted for bronchopneumonia within the first 12 months of the index hospitalization. In the 125 readmitted children, the median time to first readmission was 5.1 months (IQR 2.6--7.7); the number of hospitalizations within the first 12 months of the index hospitalization were 2.4 ± 0.8, on average. Patient demographic and baseline characteristics are presented in [Table 1](#table1-1753466619879832){ref-type="table"}. A significantly higher percentage (34.0%) of children in the readmission group had bronchial asthma *versus* children in the nonreadmission group (19.9%; *p* = 0.007). Children in the readmission group had significantly higher IgE levels \[median (IQR): 144 (46--387)\] *versus* children in the nonreadmission group \[median (IQR): 87.6 (30.6--234); *p* \< 0.001\]. Children in the readmission group also had a noticeably higher times of hospitalizations, and longer duration compared with the nonreadmission group (*p* \< 0.001). Children in the two groups were comparable in the demographic and other baseline variables (*p* \> 0.05).

###### 

Patient demographic and baseline characteristics.

![](10.1177_1753466619879832-table1)

  Variables                                All (*n* = 1099)   Nonreadmission (*n* = 974)   Readmission (*n* = 125)   *p*
  ---------------------------------------- ------------------ ---------------------------- ------------------------- ---------
  Male, *n* (%)                            593 (54.0)         528 (54.2)                   65 (52.0)                 0.641
  Median age, years (IQR)                  4 (3--6)           4 (2--6)                     4 (3--6)                  0.078
  With medical insurance, *n* (%)          1008 (91.7)        896 (92.0)                   112 (89.6)                0.361
  Family history of allergy, *n* (%)                                                                                 
   Yes                                     85 (7.7)           73 (7.5)                     12 (9.6)                  0.407
  Comorbidities, *n* (%)                                                                                             
   Bronchial asthma                        232 (21.1)         194 (19.9)                   38 (34.0)                 0.007
   Allergic rhinitis                       39 (3.5)           32 (3.3)                     7 (5.6)                   0.196
   Agranulocytosis                         28 (2.5)           25 (2.6)                     3 (2.4)                   1.000
   Anemia                                  6 (0.5)            5 (0.5)                      1 (0.8)                   0.516
   AOM                                     10 (0.9)           9 (0.9)                      1 (0.8)                   1.000
  Laboratory findings                                                                                                
   WBC (mean ± SD, 10^9^/l)                7.49 ± 2.95        7.5 ± 3.0                    7.2 ± 2.8                 0.406
   HGB (mean ± SD, g/l)                    124.3 ± 10.0       124.6 ± 9.5                  123.2 ± 11.5              0.159
   Platelets (mean ± SD, 10^9^/l)          339.5 ± 102.3      343.5 ± 103.7                327.1 ± 99.3              0.152
   Median hs-CRP (IQR), g/l                4.2 (2.9--5.9)     4.2 (2.8--5.8)               5.0 (3.5--7.0)            0.146
   Median total bilirubin (IQR), mmol/l    5.1 (4.0--6.5)     5.1 (4.0--6.5)               5.4 (4.2--6.7)            0.112
   Median ALT (IQR), U/l                   13 (11--16)        13 (11--16)                  13 (11--15.5)             0.592
   Median IgE (IQR), IU/ml                 95.8 (32.3--250)   87.6 (30.6--234)             144 (46--387)             \<0.001
  Hospitalization time (mean ± SD, days)   8.1 ± 2.4          8.0 ± 2.3                    8.8 ± 3.1                 \<0.001

ALT, alanine aminotransferase; AOM, acute *otitis media*; HGB, hemoglobin; hs-CRP, high-sensitivity C-reactive protein; IgE, immunoglobulin E; IQR, interquartile range; SD, standard deviation; WBC, white blood cell count.

The primary outcome {#section13-1753466619879832}
-------------------

Children with abnormal IgE (\>165 IU/ml) had a noticeably higher rate of bronchopneumonia-related readmission within 12 months *versus* those with normal IgE \[16.0% *versus* 8.9%, *p* \< 0.001; [Figure 2(a)](#fig2-1753466619879832){ref-type="fig"}\]. The 12-month readmission rate was 7.2%, 9.5%, 13.1% and 15.6% in the groups with the first quartile, the median, the third quartile, and highest IgE level, respectively \[*p* \< 0.001; [Figure 2(b)](#fig2-1753466619879832){ref-type="fig"}\]. The bronchopneumonia-related rate of readmission within 12 months was noticeably higher in children whose IgE levels were higher than three times the UNL (18.6%) *versus* those whose IgE levels were equal or below the UNL \[8.9%, *p* \< 0.001; [Figure 2(c)](#fig2-1753466619879832){ref-type="fig"}\]. Consistently, in children with abnormal IgE levels, those who had bronchial asthma, had a significantly higher rate of readmission than those without bronchial asthma \[18.9% *versus* 14.6%, *p* \< 0.001; [Figure 2(d)](#fig2-1753466619879832){ref-type="fig"}\].

![Bronchopneumonia-related rate of readmission within 12 months.\
(a) The bronchopneumonia-related rate of readmission within 12 months is higher with higher IgE level (\>165 IU/ml); (b) the trend for the readmission rate rises with increasing IgE level, from the lowest to highest quartile; (c) the readmission rate increased with the raised levels of IgE; (d) in children with abnormal IgE levels, those who had bronchial asthma, had a significantly higher rate of readmission than those without bronchial asthma.\
IgE, immunoglobulin E.](10.1177_1753466619879832-fig2){#fig2-1753466619879832}

Multivariate logistic regression analysis {#section14-1753466619879832}
-----------------------------------------

Multivariate logistic regression analysis showed that abnormal IgE levels were a significant risk for readmission within 12 months *versus* normal IgE levels (adjusted OR 1.781, 95% CI 1.209--2.624, *p* = 0.004; [Table 2](#table2-1753466619879832){ref-type="table"}). Compared with children whose IgE levels were in the first quartile, children whose IgE levels were in the third quartile had a significantly higher risk of 12-month readmission (adjusted OR 1.922 and 2.149, 95% CI 1.078--3.424 and 1.214--3.802, *p* = 0.027 and 0.009, respectively). Compared with those with normal IgE levels, children whose IgE levels were more than three times the UNL had a higher risk of readmission (adjusted OR 2.037, 95% CI 1.172--3.540, *p* = 0.012). At the same time, the risk of readmission was significantly higher in children with abnormal IgE and with bronchial asthma than in children with normal IgE levels and without bronchial asthma (adjusted OR 2.548 and 1.918, 95% CI 1.490--4.358 and 1.218--3.020, *p* = 0.001 and 0.005, respectively).

###### 

Logistic regression analysis of association between IgE levels and readmission.

![](10.1177_1753466619879832-table2)

  Variables                    Crude   Adjusted^[\*](#table-fn2-1753466619879832){ref-type="table-fn"}^                                             
  ---------------------- ----- ------- ------------------------------------------------------------------ ------- --------- ------- ------- ------- ---------
  **Lg(IgE)**                  2.008   1.461                                                              2.760   \<0.001   1.876   1.354   2.600   \<0.001
  **IgE** (IU/ml)                                                                                                                                   
  \>165                  381   1.948   1.338                                                              2.835   \<0.001   1.781   1.209   2.624   0.004
  ⩽165                   718   Ref     Ref                                                                                                          
  **IgE** (IU/ml)                                                                                                                                   
  ⩾251                   275   2.372   1.356                                                              4.151   0.002     2.149   1.214   3.802   0.009
  95--25                 274   1.936   1.090                                                              3.439   0.024     1.922   1.078   3.424   0.027
  32.3--95               274   1.342   0.730                                                              2.466   0.343     1.364   0.741   2.511   0.319
  \<32.3                 276   Ref     Ref                                                                                                          
  **IgE** (IU/ml)                                                                                                                                   
  \>495 (3 × UNL)        118   2.342   1.379                                                              3.977   0.002     2.037   1.172   3.540   0.012
  330--495 (2 × UNL)     109   1.758   0.975                                                              3.169   0.061     1.623   0.893   2.950   0.112
  165--330 (1 × UNL)     154   1.794   1.075                                                              2.994   0.025     1.712   1.022   2.869   0.041
  ⩽165                   718   Ref     Ref                                                                                                          
  **IgE** (IU/ml)                                                                                                                                   
  \>165 and with BA      127   2.624   1.544                                                              4.458   \<0.001   2.548   1.490   4.358   0.001
  \>165 and without BA   254   1.920   1.221                                                              3.020   0.005     1.918   1.218   3.020   0.005
  ⩽165 and with BA       105   1.732   0.920                                                              3.261   0.089     1.731   0.917   3.264   0.090
  ⩽165 and without BA    613   Ref     Ref                                                                                                          

Adjusted: sex, age, or BA.

BA, bronchial asthma; CI, confidence interval; IgE, immunoglobulin E; Lg(IgE), log^10^IgE; OR, odds ratio; Ref, reference; UNL, upper normal limit.

The Kaplan--Meier analysis showed that patients with abnormal IgE had significantly higher risk of 12-months readmission than those with normal IgE \[log-rank test, *p* \< 0.001, [Figure 3(a)](#fig3-1753466619879832){ref-type="fig"}\]. With the IgE level increased, the risk of readmission was increased \[log-rank test, *p* \< 0.001, [Figure 3(b)](#fig3-1753466619879832){ref-type="fig"}\]. Consistently, compared with those whose IgE levels were equal or below the UNL, the risk of readmission was noticeably higher in children whose IgE levels were higher than three times the UNL \[log-rank test, *p* \< 0.001, [Figure 3(c)](#fig3-1753466619879832){ref-type="fig"}\]. Moreover, those who had bronchial asthma, had a significantly higher risk of readmission than those without bronchial asthma \[log-rank test, *p* \< 0.001, [Figure 3(d)](#fig3-1753466619879832){ref-type="fig"}\].

![IgE levels *versus* rates of readmission.\
(a) The cumulative risk of readmission increases in a higher IgE level (\>165 IU/ml); (b) The cumulative risk of readmission increases with the increasing of IgE level, from the lowest to highest quartile; (c) The cumulative risk of readmission was increasing with the raised levels of IgE; (d) In children with abnormal IgE levels, those who had bronchial asthma, had a significantly increased cumulative risk of readmission than those without bronchial asthma.\
IgE, immunoglobulin E.](10.1177_1753466619879832-fig3){#fig3-1753466619879832}

Discussion {#section15-1753466619879832}
==========

This study showed that approximately 1 in 10 children was readmitted within the first 12 months of the index hospitalization. Furthermore, we found that higher IgE levels were an independent risk for repeated hospitalization within the first 12 months of the index hospitalization.

Bronchial pneumonia is one of the most common diseases in the pediatric emergency department. Unexpected repeated hospitalization in children has a serious negative impact on children and their families. Our study found that the incidence of repeated hospitalization within the first 12 months of the index hospitalization was as high as 11.4%, suggesting that the inpatient pediatric population with bronchopneumonia have a larger proportion of rehospitalization. Thus, it is necessary to actively identify risk factors that affect rehospitalization of children in order to provide timely intervention, thereby reducing the incidence of repeated hospitalization. Allergic diseases are known to be important contributors to the occurrence of pneumonia and aggravate the condition,^[@bibr18-1753466619879832]^ and the level of IgE is closely related to the occurrence of allergic diseases.^[@bibr4-1753466619879832]^ A study has found that repeated attacks of bronchial pneumonia in children are often accompanied by a significant increase in IgE levels,^[@bibr11-1753466619879832],[@bibr12-1753466619879832]^ and our findings further support this conclusion. We demonstrated that IgE levels were significantly higher in children who were hospitalized repeatedly, so IgE levels in children with bronchopneumonia deserve more clinical attention.

This study found that regardless of how IgE levels were stratified in children, the incidence of repeated hospitalization within the first 12 months of the index hospitalization was significantly higher in those with higher IgE levels, indicating that physicians should pay more attention to IgE levels in children, and providing a new approach as to prevention of repeated hospitalization for this population of children. It also reminds caregivers of children with high IgE levels to take preventive measures in terms of life care, so as to avoid the occurrence of repeated hospitalization. We also found that when the IgE level exceeded three times of the UNL, the risk of repeated hospitalization within the first 12 months of the index hospitalization had a significant increase. Previous research showed that the concentration of pH in exhaled breath condensate was found to be decreased and related to airway inflammation in asthmatic patients.^[@bibr19-1753466619879832]^ Children with bronchial asthma are often accompanied by the presence of bronchial pneumonia, pneumonia, and other diseases.^[@bibr10-1753466619879832]^ The proportion of bronchial asthma in children with repeated hospitalization was significantly elevated. Further analysis revealed that high IgE levels were also an independent risk factor for repeated hospitalization even if the bronchial asthma was cured. If children with abnormal IgE levels have bronchial asthma, the risk of repeated hospitalization within the first 12 months of the index hospitalization is particularly significant, suggesting that for this group of children, while controlling bronchial asthma, attention should be paid to the IgE levels and the risk of recurrent bronchopneumonia.

Conclusion {#section16-1753466619879832}
==========

Our study shows that IgE levels are strongly associated with repeat hospitalization within the first 12 months of the index hospitalization in children aged over 1 year with bronchopneumonia and may serve as a predictor of repeated hospitalization in this group of children. Based on the results of this study, it may provide a new basis for phenotypic classification of children with bronchopneumonia. Therefore, future studies should focus on the pathophysiological mechanisms of children with high IgE levels, and whether the intervention of such children can reduce the incidence of repeated hospitalization.

Limitation {#section17-1753466619879832}
----------

Our study has several limitations. First, it is a retrospective study. The data were collected from the hospital's electronic records and may have some omissions. Second, the diagnosis of bronchopneumonia is mainly based on the clinical features and is supported by chest radiography. Thus, bronchopneumonia may not be retrieved in full; the diagnosis of bronchopneumonia and asthma lacking a definitive laboratory test or biomarker acceptable to all disciplines; and the symptoms are nonspecific, so it is difficult to make a clear distinction between asthma and other lower respiratory tract infections, including bronchitis, bronchiolitis, and so on. Some studies suggest that the relationship between high IgE levels and the occurrence of pneumonia may be related essentially to the pneumonia caused by bronchial asthma.^[@bibr20-1753466619879832]^ Children with high IgE levels in this study included some cases with underlying bronchial asthma, which may lead to bias. Another limitation of the study is that a healthy control group is lacking; all we see are correlation, we never see the causal relationship and seasonal variation, comorbidities. Lifestyle after the first episode may introduce biases, but this research is mainly to confirm the correlation between IgE levels and readmission, and the hope of attracting the clinical physician's attention. Family history of allergy was taken from the parents' retrospective history, which potentially may be incorrect; we do not expect those limitations to have biased our results. Another limitation was that not all children have etiologic diagnoses; when analyzing the subset of patients with etiologic diagnoses, the association between IgE and bronchopneumonia became stronger. Overall, our study shows that IgE may serve as a predictor of repeated hospitalization in children with bronchopneumonia. Our study generates some questions, and further studies are warranted.
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